Conditions: Ankylosing Spondylitis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 223
Healthy volunteers: no

Brief summary:
Primary Objective:

* To assess the long term safety of Sarilumab (SAR153191/REGN88) in participants with ankylosing spondylitis (AS)

Secondary Objective:

* To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in participants with AS

Detailed description:
The maximum study duration per participant was to be 267 weeks (approximately 5 years) broken down as follows:

* screening up to a maximum of 1 week;
* treatment up to a maximum of 260 weeks;
* follow-up of 6 weeks after treatment discontinuation.

Arms:
arm 1: Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.

Interventions: intervention 1: Sarilumab
Intervention descriptions: intervention 1: Pharmaceutical form: solution for injection

Route of administration: subcutaneous

Protocol document: